US 12,290,510 B2
Polyvalent derivatives of emoxypine
Claude Nicolau, Boston, MA (US); Jean-Marie Lehn, Boston, MA (US); Renald Thinard, Boston, MA (US); and Youssef Atoini, Boston, MA (US)
Assigned to Riesner Verwaltungs GMBH, Düsseldorf (DE)
Appl. No. 17/427,395
Filed by Riesner Verwaltungs GMBH, Düsseldorf (DE)
PCT Filed Feb. 7, 2020, PCT No. PCT/US2020/017192
§ 371(c)(1), (2) Date Jul. 30, 2021,
PCT Pub. No. WO2020/163704, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,323, filed on Feb. 7, 2019.
Prior Publication US 2022/0096451 A1, Mar. 31, 2022
Int. Cl. A61K 31/444 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/444 (2013.01) [A61P 25/28 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A method for treating or preventing a synucleinopathy, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6) alkyl, (C1-C6) alkoxy, halo (C1-C6) alkyl, (C2-C6) alkenyl, (C3-C8) cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6 and
wherein the synucleinopathy is a condition characterized by Lewy bodies; or
a compound of Formula II:

OG Complex Work Unit Chemistry
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R1, R2, R3, or R4 is independently halo, nitro, OH, (C1-C6) alkyl, (C1-C6) alkoxy, halo (C1-C6) alkyl, (C2-C6) alkenyl, (C3-C8) cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6, and
wherein the synucleinopathy is a condition characterized by Lewy bodies.